Myotonachol Disease Interactions

The use of cholinergic agonists is contraindicated in patients with uncontrolled reactive airway disease. Cholinergic agonists inhibits the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.

The use of cholinergic agonists, such as bethanechol and pilocarpine, is contraindicated in patients with pronounced bradycardia, hypotension/hypertension, coronary artery disease or conduction disorders.

The use of cholinergic agonists is contraindicated in patients with peptic ulcers, mechanical GI obstruction, acute GI inflammatory conditions, or urinary obstruction. Cholinergic activity may result in an increase in gastric acid secretion, GI motility, and gastric contractions. In patients with urinary retention, urinary reflux may occur if the sphincter fails to relax when the bladder is contracted by cholinergic stimulation. The reflux of urine from the bladder can cause infection in the kidneys and upper urinary tract if bacteriuria is present.

The use of cholinergic agents may be contraindicated in patients with hyperthyroidism. Atrial fibrillation has occurred in hyperthyroid patients administered a cholinergic agonist.

The use of cholinergic agonists may be contraindicated in patients with parkinsonism. Cholinergic agonists directly stimulates the parasympathetic nervous system inducing acetylcholinergic effects. Symptoms of Parkinson's disease may be exacerbated.

The use of cholinergic agonists may be contraindicated in patients with seizure disorders. Cholinomimetics have been associated with convulsions.